• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Avadel Pharmaceuticals plc

    7/29/25 3:01:47 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVDL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Avadel Pharmaceuticals PLC

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    G29687103

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G29687103


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    107,614.00
    7Sole Dispositive Power

    5,361,014.00
    8Shared Dispositive Power

    203,245.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,564,259.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.74 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Avadel Pharmaceuticals PLC
    (b)Address of issuer's principal executive offices:

    Block 10-1 Blanchardstown, Corporate Park, Ballycoolin, Dublin, L2, D15
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    G29687103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    5564259
    (b)Percent of class:

    5.74  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    107614

     (iii) Sole power to dispose or to direct the disposition of:

    5361014

     (iv) Shared power to dispose or to direct the disposition of:

    203245

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:07/29/2025
    Get the next $AVDL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVDL

    DatePrice TargetRatingAnalyst
    7/18/2025$22.00Buy
    H.C. Wainwright
    2/11/2025$12.00Buy
    Deutsche Bank
    6/12/2024$27.00Buy
    Rodman & Renshaw
    3/5/2024$27.00 → $29.00Outperform
    Oppenheimer
    3/5/2024$21.00 → $25.00Buy
    H.C. Wainwright
    3/5/2024$20.00 → $22.00Buy
    Needham
    2/6/2024$21.00Buy
    UBS
    11/30/2022$6.50 → $11.00Hold → Buy
    Jefferies
    More analyst ratings

    $AVDL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Palczuk Linda bought $39,640 worth of Ordinary Shares (5,000 units at $7.93), increasing direct ownership by 8% to 67,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/22/25 4:13:34 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thornton Peter J. bought $80,450 worth of Ordinary Shares (10,000 units at $8.04), increasing direct ownership by 11% to 104,055 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/14/25 4:24:12 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ende Eric J bought $235,218 worth of Ordinary Shares (30,000 units at $7.84), increasing direct ownership by 17% to 208,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/14/25 4:22:57 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

    DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference: Fireside chat on Friday, September 5 at 11:00 a.m. ET.Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Tuesday, September 9 at 1:05 p.m. ET.H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Wednesday, September 10 at 9:30 a.m. ET. A live webcast of these events, as well as archived recordings, will be available on Avadel's Invest

    8/29/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to eight (8) new employees to purchase 60,400 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the

    8/7/25 4:05:00 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

    -- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH by end of 2025 -- -- Avadel management to host conference call today at 8:30 a.m.

    8/7/25 7:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mccamish Mark Anthony was granted 11,000 units of Ordinary Shares, increasing direct ownership by 100% to 22,000 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    7/31/25 4:10:52 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Palczuk Linda was granted 11,000 units of Ordinary Shares, increasing direct ownership by 16% to 78,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    7/31/25 4:09:56 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thornton Peter J. was granted 11,000 units of Ordinary Shares, increasing direct ownership by 11% to 115,055 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    7/31/25 4:09:06 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Avadel Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $22.00

    7/18/25 9:08:21 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank initiated coverage on Avadel Pharmaceuticals with a new price target

    Deutsche Bank initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    2/11/25 7:00:38 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Avadel Pharmaceuticals with a new price target

    Rodman & Renshaw initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $27.00

    6/12/24 7:06:25 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Avadel Pharmaceuticals plc

    SCHEDULE 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    8/14/25 11:00:36 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Avadel Pharmaceuticals plc

    S-8 - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

    8/7/25 4:28:29 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Avadel Pharmaceuticals plc

    S-3ASR - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

    8/7/25 4:06:53 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Leadership Updates

    Live Leadership Updates

    View All

    Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer

    DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's commercial strategy, structure, organization, and related operations, including supply chain. "Susan is an accomplished biopharma executive with a track record of strategic leadership and excellence in commercializing innovative medicines," said Gregory J. Divis, Chief Executive Officer of Avadel. "Her expertise will be invaluable at this critical

    5/13/25 4:15:00 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

    DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. "We're delighted to welcome Kevin to Avadel – he's a great addition to our team with the deep experience to help us drive success at this important time," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Kevin's expertise and proven track record in build

    2/24/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement

    DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical organizations. "We are thrilled to welcome Sev to the Avadel team," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Providing comprehensive support to patients and providers and continuously improvin

    1/22/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Financials

    Live finance-specific insights

    View All

    Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

    -- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH by end of 2025 -- -- Avadel management to host conference call today at 8:30 a.m.

    8/7/25 7:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7

    DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are

    7/31/25 8:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

    -- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) --         -- On track to complete enrollment in

    5/7/25 7:00:00 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/14/24 6:10:30 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/13/24 5:58:54 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/13/24 5:00:57 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care